EFFECT OF DISEASE AND DRUG-TREATMENT ON BLOOD SEROTONIN AND MONOAMINE-OXIDASE-B ACTIVITY IN PARKINSONS-DISEASE

被引：4

作者：

VANKEMPEN, GMJ ^{[1
]}

JANJUA, R ^{[1
]}

ROOS, RAC ^{[1
]}

机构：

[1] LEIDEN STATE UNIV,ACAD HOSP,DEPT NEUROL,2333 AA LEIDEN,NETHERLANDS

来源：

CLINICAL NEUROLOGY AND NEUROSURGERY | 1995年 / 97卷 / 02期

关键词：

DRUG EFFECTS; 5-HYDROXYTRYPTAMINE; MONOAMINE OXIDASE; PARKINSONS DISEASE; SELEGILINE; SEROTONIN;

D O I：

10.1016/0303-8467(95)00011-8

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Serotonin (5-hydroxytryptamine, 5HT) content and monoamine oxidase (MAO) activity were determined in whole blood of patients with Parkinson's disease (PD) with and without drug treatment and compared with controls. From that comparison a significant reduction in platelet 5HT became apparent in PD. Selegiline, which was always used in combination with L-dopa, not only inhibited MAO activity, as expected, but it also appeared to induce an increase in 5HT content.

引用

页码：131 / 133

页数：3

共 50 条

[41] Controversies in Neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease
Loehle, Matthias
Reichmann, Heinz
BMC NEUROLOGY, 2011, 11
[42] Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease
Tao, Deng
Wang, Yue
Bao, Xiu-Qi
Yang, Bei-Bei
Gao, Fan
Wang, Lin
Zhang, Dan
Li, Li
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 173 : 203 - 212
[43] Platelet MAO-B Activity and Serotonin Content in Patients with Dementia: Effect of Age, Medication, and Disease
Zsuzsa Mészáros
Dóra Borcsiczky
Mónika Máté
József Tarcali
Tamás Szombathy
Kornélia Tekes
Kálmán Magyar
Neurochemical Research, 1998, 23 : 863 - 868
[44] Platelet MAO-B activity and serotonin content in patients with dementia:: Effect of age, medication, and disease
Mészaros, Z
Borcsiczky, D
Máté, M
Tarcali, J
Szombathy, T
Tekes, K
Magyar, K
NEUROCHEMICAL RESEARCH, 1998, 23 (06) : 863 - 868
[45] 6-Benzyloxyphthalides as selective and reversible monoamine oxidase B inhibitors with antioxidant and anti-neuroinflammatory activities for Parkinson's disease treatment
Song, Qing
Yu, Guangjun
Li, Wei
Xu, Yidan
Cong, Shiqin
Liu, Xiuxiu
Tan, Zhenghuai
Deng, Yong
BIOORGANIC CHEMISTRY, 2022, 120
[46] The effect of monoamine oxidase-B inhibitors on the alleviation of depressive symptoms in Parkinson's disease: meta-analysis of randomized controlled trials
Huang, Yao Hsien
Chen, Jia Hung
Loh, El Wui
Chan, Lung
Hong, Chien Tai
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2021, 11
[47] The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease
Bialecka, M
Drozdzik, M
Klodowska-Duda, G
Honczarenko, K
Gawronska-Szklarz, B
Opala, G
Stankiewicz, J
ACTA NEUROLOGICA SCANDINAVICA, 2004, 110 (04): : 260 - 266
[48] Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson’s disease: a multiple treatment comparison meta-analysis
Caroline D. Binde
Ingunn F. Tvete
Jørund I. Gåsemyr
Bent Natvig
Marianne Klemp
European Journal of Clinical Pharmacology, 2020, 76 : 1731 - 1743
[49] Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis
Binde, Caroline D.
Tvete, Ingunn F.
Gasemyr, Jorund, I
Natvig, Bent
Klemp, Marianne
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 76 (12) : 1731 - 1743
[50] Synthesis and evaluation of 6-substituted 3-arylcoumarin derivatives as multifunctional acetylcholinesterase/monoamine oxidase B dual inhibitors for the treatment of Alzheimer's disease
Wang, Zhi-Min
Li, Xue-Mei
Xue, Gui-Min
Xu, Wei
Wang, Xiao-Bing
Kong, Ling-Yi
RSC ADVANCES, 2015, 5 (126): : 104122 - 104137

← 1 2 3 4 5 →